Hypera Financial Statements From 2010 to 2024
| HYPE3 Stock | BRL 20.27 0.09 0.45% |
Check Hypera SA financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Hypera SA's main balance sheet or income statement drivers, such as , as well as many indicators such as . Hypera financial statements analysis is a perfect complement when working with Hypera SA Valuation or Volatility modules.
Hypera |
Hypera SA Company Profit Margin Analysis
Hypera SA's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Hypera SA Profit Margin | 0.23 % |
Most of Hypera SA's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hypera SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Hypera SA has a Profit Margin of 0.2299%. This is 102.05% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The profit margin for all Brazil stocks is 118.1% lower than that of the firm.
Hypera SA Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Hypera SA's current stock value. Our valuation model uses many indicators to compare Hypera SA value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Hypera SA competition to find correlations between indicators driving Hypera SA's intrinsic value. More Info.Hypera SA is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers reporting about 0.42 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Hypera SA is roughly 2.37 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Hypera SA's earnings, one of the primary drivers of an investment's value.About Hypera SA Financial Statements
Hypera SA shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Hypera SA investors may analyze each financial statement separately, they are all interrelated. The changes in Hypera SA's assets and liabilities, for example, are also reflected in the revenues and expenses on on Hypera SA's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
It offers branded prescription products under the Mantecorp Farmasa, Episol, Predsim, Alivium, Lisador, Rinosoro, Celestamine, Maxsulid, Diprospan, Mioflex-A, and Addera D3 brands dermo-cosmetics products under the Mantecorp Skincare brands and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. Hypera S.A. was founded in 2001 and is headquartered in So Paulo, Brazil. HYPERA ON operates under Drug ManufacturersSpecialty Generic classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 8918 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Hypera Stock Analysis
When running Hypera SA's price analysis, check to measure Hypera SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hypera SA is operating at the current time. Most of Hypera SA's value examination focuses on studying past and present price action to predict the probability of Hypera SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hypera SA's price. Additionally, you may evaluate how the addition of Hypera SA to your portfolios can decrease your overall portfolio volatility.